Vimta Labs Limited

Vimta Labs Limited

Vimta Labs Limited informed the National Stock Exchange (NSE) that it has submitted a copy of a newspaper publication as part of its regulatory disclosure obligations. The filing does not contain any financial, operational or strategic details; it is a procedural compliance submission. No impact on the company's earnings, growth prospects or balance sheet is implied by this announcement.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange about the link of the recording of the Q1 FY 2026-27 Earnings/Investor Call held on July 20, 2026, available on the company's website.

Vimta Labs Limited

Vimta Labs Limited has announced its Q1 FY27 results, with a total income of ₹1,129 Mn, up 13.7% YoY. EBITDA margins were at 36.4% and PAT margin was at 18.6%. The company has also commenced operations in Biologics contract research and development services (CRADS).

Vimta Labs Limited

Vimta Labs Limited has released its Q1 FY27 investor presentation, highlighting its Q1 FY27 earnings, company overview, and future growth prospects.

Vimta Labs Limited

Vimta Labs Limited has submitted its financial results for the period ended June 30, 2026.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange regarding 'Update on Payment of Dividend'. The company has paid a dividend of ₹2/- per equity share of face value ₹2/- each to eligible shareholders on 04 July 2026.

Vimta Labs Limited

Vimta Labs Limited has informed the Exchange regarding allotment of 17,549 securities pursuant to ESOP/ESPS at its meeting held on July 01, 2026. The paid-up share capital of the Company has increased from ₹ 8,93,38,710 consisting of 4,46,69,355 equity shares having a face value of ₹ 2/- each to ₹ 8,93,73,808 consisting of 4,46,86,904 equity shares having a face value of ₹ 2/- each.